| Segment Reporting Disclosure [Text Block] |
14. Segment Information The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands): Cost of goods sold is directly related to product sales only. Revenues derived from co promote revenue, which made up all of the Dermatology Product Sales in the first quarter had no cost of goods sold. As a result, cost of goods sold was only recorded in the three months ended June 30, 2016. | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Three Months Ended June 30, 2016 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | 982 | | $ | 1,248 | | $ | 2,230 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (1,998) | | | - | | | (1,998) | | | Research and development | | | - | | | (8,407) | | | (8,407) | | | General and administrative | | | - | | | (6,637) | | | (6,637) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (1,340) | | $ | (13,796) | | $ | (15,136) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Three Months Ended June 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | - | | $ | - | | | Direct cost of goods | | | - | | | - | | | - | | | Sales and marketing costs | | | (727) | | | - | | | (727) | | | Research and development | | | - | | | (3,959) | | | (3,959) | | | General and administrative | | | - | | | (3,076) | | | (3,076) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (727) | | $ | (7,035) | | $ | (7,762) | | | Segment assets | | $ | 1,569 | | $ | 82,130 | | $ | 83,699 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology | | | | | Six Months Ended June 30, 2016 | | Sales | | Product Development | | Consolidated | | | Net Revenue | | $ | 1,364 | | $ | 1,526 | | $ | 2,890 | | | Direct cost of goods | | | (324) | | | - | | | (324) | | | Sales and marketing costs | | | (3,884) | | | - | | | (3,884) | | | Research and development | | | - | | | (16,244) | | | (16,244) | | | General and administrative | | | - | | | (12,665) | | | (12,665) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (2,844) | | $ | (27,383) | | $ | (30,227) | | | Segment assets | | $ | 3,058 | | $ | 95,004 | | $ | 98,062 | | | | | Dermatology | | Pharmaceutical and | | | | | | | Products | | Biotechnology Product | | | | | Six Months Ended June 30, 2015 | | Sales | | Development | | Consolidated | | | Net Revenue | | $ | - | | $ | 500 | | $ | 500 | | | Direct cost of goods | | | - | | | - | | $ | - | | | Sales and marketing costs | | | (1,300) | | | | | | (1,300) | | | Research and development | | | - | | | (13,053) | | | (13,053) | | | General and administrative | | | - | | | (5,980) | | | (5,980) | | | | | | | | | | | | | | | Segment loss from operations | | $ | (1,300) | | $ | (18,533) | | $ | (19,833) | | | Segment assets | | $ | 1,569 | | $ | 82,130 | | $ | 83,699 | | Significant Customers For the three months ended June 30, 2016, three of our customers accounted for more than 10.0% of our total revenue in the amount of $0.3 million, $0.3 million, and $0.3 million, respectively. The revenue from these customers is captured in the product revenue, net line item within the Condensed Consolidated Statement of Operations. For the six months ended June 30, 2016, three of our customers accounted for more than 10.0% of our total revenue in the amount of $0.6 million, $0.3 million, and $0.3 million, respectively. At June 30, 2016, three of our customers accounted for more than 10.0% of our total accounts receivable balance in the amount of $0.4 million, $0.4 million and $0.1 million, respectively.
|